Bio-Thera Solutions
Biosimilar developer, China. 3 development products across 3 molecules: bevacizumab, tocilizumab, ustekinumab.
About Bio-Thera Solutions
Bio-Thera, based in Guangzhou, was among the first Chinese companies to bring antibody biosimilars to Western markets. Its bevacizumab is sold by Sandoz in the United States and Europe, its tocilizumab was the first tocilizumab biosimilar approved in the United States, sold by Biogen and Stada, and its ustekinumab is sold by Hikma in the United States.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Bevacizumab | Avzivi BAT1706 | Dec 2023 | Jul 2024 | · | · | · | · | · | 2/7 |
| Tocilizumab | Tofidence / Tocilizumab STADA BAT1806 | Sep 2023 | Jun 2024 | MHRA | · | · | · | · | 3/7 |
| Ustekinumab | Starjemza BAT2206 | May 2025 | · | · | · | · | · | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
Companies on the same molecules
Developers whose portfolios overlap most with Bio-Thera Solutions, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- FDASep 2023Tofidence, tocilizumab
- FDADec 2023Avzivi, bevacizumab
- EMAJun 2024Tocilizumab STADA, tocilizumab
- EMAJul 2024Avzivi, bevacizumab
- FDAMay 2025Starjemza, ustekinumab
Compare Bio-Thera Solutions with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant